ABOUT DIA
For more than 50 years, DIA (the Drug Information Association), a non-profit association, has served as a global forum for all those involved in healthcare product development and lifecycle management to exchange knowledge and collaborate in a neutral setting. DIA is an essential resource that provides opportunities to extend debate and discussion to advance scientific and medical innovation. DIA fosters innovation to improve health and well-being worldwide by: Providing invaluable forums to exchange vital information and discuss current issues related to healthcare products, technologies, and services; Delivering customized learning experiences; Building, maintaining, and facilitating trusted relationships with and among individuals and organizations that drive and share DIA values and mandates; and offering a multidisciplinary neutral environment, respected globally for integrity and relevancy. DIA is your essential partner in catalyzing knowledge creation and sharing to accelerate healthcare product development.
VIDEOS
This video gives a two minute review of the global navigation, content organization, global search, and filtering options available on the DIA platform.
This video explains the benefits of access to the recorded sessions of over 60 global meetings per year as a member of DIA.
DIA NOW Sample video - Patient engagement initiatives are shown to increase chances of regulatory approval and accelerate development timelines.
FDARA Section 504 eliminated the orphan exemption for pediatric studies for cancer drugs and instead empowers the FDA to require pediatric assessments of new therapies.
This webinar recording will give an overview of challenges and successes of implementation of eCTD in both a small biotech setting and in academia, as these areas of industry face additional challenges that most midsize and large companies may not have.
A video overview of the valuable content that can be accessed as a DIA NOW user.
CONTACT INFORMATION
DIA
800 Enterprise Road, Suite 200
Horsham, PA 19044-3595
UNITED STATES
Phone: 215.442.6100
Fax: 215.442.6199
Contact: Michelle Rovner
SOLUTIONS
FEATURED ARTICLES
- Found in Translation: A Tumultuous Year in Review
- New Drug Approvals in China 2020
- Jump In, Be Brave, Have The Conversation – Reducing Health Disparities Among Minority Patients
- Biosimilar Savings And Their Price: BPCIA Turns Ten
- Regulators Promote Reliance As 21st Century Best Practice
- Regulatory And Clinical Science Align To Fight COVID-19
- DIA Keynote Calls For Expanded COVID-19 Trial Parameters
- Experts From China Speak On Conducting Clinical Trials During Covid-19: Part 2
- Conducting Clinical Trials During COVID-19: Case Studies From The Perspectives Of Sponsor, CROs, Sites, And IP & CTS Distributors
- Experts From China Speak On Conducting Clinical Trials During The Pandemic
- Translating Clinical Trials Into Clinical Benefit
- EU Business And Data Needs Converge Through Telematics
- How Continuous Publishing Speeds Regulatory Submissions
- DIA Upcoming Face-To-Face Trainings And Online Learning
- Pharmacovigilance And Risk Management In 2020: A Global Perspective
- Pharmacovigilance: Towards 2020 And Beyond
- Safety, Pharmacovigilance, And Risk Management Plans In China
- FDA’s Sentinel System: Strategies For Expansion And Transformation
- New Ethics And Consent Guidelines Pillars For Safety In India
- WHO 2030 Framework For Efficient, Effective Regulation
- AI In Drug Discovery And Development: Emerging Technologies And Applications
- Regulatory Perspective: Digital Health Technology Tools
- Will New Technologies Accelerate Approval Of New Therapies?
- Landmark AMA To Rely On Regulatory Reliance
- How Do You Put Your Disease On The Agenda?
- Real World Data Expanding Into Label Expansion
- Clinical Trial Diversity Begins (And Ends) With Patients First
- Imaging Data Plus AI “One Of The Best Combinations”
- Empowering Today’s Patients To Help Tomorrow’s
- New Sources Changing the Meaning of Evidence?
- Califf: Digitization Will Return Humanity to Medicine
- AI Research Can Optimize Clinical/Operational Effectiveness
- Has Joining ICH Accelerated Innovation In China?
- MID-NET Among PMDA’s First Steps Into RWE
- Regulatory Science 2019: Leading or Holding Back Innovation?
- 23andMe: Information Empowering Patient Action
- The Patient’s Most Engaging Question: Why?
- Genetics Leading Modern Revolution In Cancer Care
- Challenges In Generic Drug Safety & Surveillance
- Automation No Substitute For Scientific Leadership
- Advanced Therapies Moving Upon Combination Platforms
- Interview With A DIA 2018 Patient Scholar
- Advancing The Science Of Study Endpoints
- Analyzing Innovation’s Progress In Gottlieb Era
- Triple-A RWE: Adequate Data, Appropriate Designs, Actionable Evidence
- Disparities Between FDA/EMA Review Processes
- FDA Leadership On Future Biologics And EMA/FDA Cooperation
- Global Perspectives On Patient Engagement
- Regulatory & Ethical Considerations in a Pediatric Trial
- “My Voice Needed to Be Heard”
- Block Chain, AI, Internet Of Things: Future Of PharmaTech?
- Value-Based Assessment & Contracting: What Needs to Be Done?
- Regulatory Landscape of Drug-Device Combination Products
- Integrating Genetic Medicine Into Clinical Care
- Pace Of Innovation vs. Regulation: Combination Challenge
- FDA Guidances Related To Combination Products
- Running Away from Addiction Has Caught Up with U.S.
- US Generic Drug Policy: Less Cost, Same Impact
- DIA 2018 Co-Chair: Patient Activists Are "Our Best Friends"